Under the collaboration, Repertoire and Yale will work together to identify subsets of T cells obtained from the cerebrospinal fluid of MS patients and determine the pathogenic T cells responsible for the disease and the antigens that activate them. Yale researchers will provide human T-cell receptor (TCR) sequences to Repertoire, which will then use its proprietary Decode platform to determine novel antigens that these TCRs identify.

The goal of the collaboration is to uncover unique insights into how T cells contribute to the pathogenesis of the neurodegenerative disease.

The Yale research team will be led by Dr. David Hafler, a professor of neurology and immunobiology at the Yale School of Medicine, and neurologist in chief at Yale New Haven Hospital.

Financial details of the collaboration were not disclosed.

Aptorum licenses immunomodulators from Yale
Aptorum has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators.

Repertoire Immune Medicines secures $189M
Repertoire Immune Medicines has completed a round of financing, raising $189 million to further expand its Decode discovery platform, accelerate...

Taysha establishes additional collaboration for minigene payloads
Taysha Gene Therapies has established a multiyear collaboration with a team of Yale University researchers. The goal is to advance next-generation minigene...

Foundation, medical schools partner on gene therapy for H-ABC
The nonprofit organization Foundation to Fight H-ABC has signed an agreement with the University of Massachusetts Medical School and Yale University to...